Company intelligence / Profile preview

Delta

Carapachay, Buenos Aires, Argentina

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Delta Biotech SA is an active pharmaceutical ingredient (API) manufacturer specializing in prostaglandins and vitamin D derivatives (calcitriol, alfacalcidol, calcipotriol, latanoprost, travoprost). Based in Argentina with two manufacturing plants, it supplies commercial-stage APIs globally for drugs targeting conditions such as calcium metabolism disorders, osteoporosis, psoriasis, and glaucoma. While the Argentine entity is independent, a related former UK entity, Delta Biotechnology Ltd., was acquired by Novozymes A/S.

Therapeutic areas: DermatologyOphthalmologyEndocrinology
Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Partnerships

Synergistic collaborations and bulk API supply partnerships, details not disclosed

Beyond the preview

Go deeper on Delta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta.

Explore the full profile